文献速递肝病

预测乙型肝炎病毒相关慢加急性肝衰竭的发生

Predicting the Onset of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-03-23

研究基于1373例乙型肝炎病毒相关慢性肝病急性恶化患者的前瞻性临床数据,开发并验证了预测慢加急性肝衰竭(ACLF)发生的预后评分。该评分由总胆红素、国际标准化比值、丙氨酸氨基转移酶和铁蛋白4个预测因子构成,对7/14/28天ACLF发生的C指数分别为0.928/0.925/0.913,显著高于其他5种评分(均P < .001)。风险分层以6.3为界分为高风险(≥6.3)和低风险(<6.3)两层,外部验证组进一步证实了上述结果。

要点

  • 新评分可准确预测乙型肝炎病毒相关慢性肝病急性恶化患者7/14/28天ACLF的发生。
  • 评分由总胆红素、国际标准化比值、丙氨酸氨基转移酶和铁蛋白4个预测因子构成。
  • 风险分层以6.3为界分为高风险(≥6.3)和低风险(<6.3)两层。

核心结论

  • 基于4个预测因子的新预后评分能准确预测乙型肝炎病毒相关慢性肝病急性恶化患者7/14/28天ACLF的发生,并可能用于指导临床管理。

研究设计与样本

  • 研究利用1373例乙型肝炎病毒相关慢性肝病急性恶化患者的前瞻性临床数据,识别临床特征并开发预测ACLF发生的预后评分。
  • 采用中国重型乙型肝炎研究组(COSSH)-ACLF标准评估患者,入院时非ACLF患者903例(其中1例在5天时接受移植)纳入分层:7天内进展为ACLF者71例,未进展者831例。
  • 外部验证组进一步证实了上述结果。

主要发现

  • 总胆红素、国际标准化比值、丙氨酸氨基转移酶和铁蛋白4个预测因子与7天ACLF发生显著相关。
  • 新评分对7/14/28天ACLF发生的C指数分别为0.928/0.925/0.913,显著高于其他5种评分(COSSH-ACLF发展评分/终末期肝病模型评分/终末期肝病模型钠评分/COSSH-ACLF评分/慢性肝衰竭联盟ACLF评分;均P < .001)。
  • 新评分在预测误差改善、时间依赖受试者工作特征曲线、概率密度函数评估和校准曲线方面均显示对7/14/28天ACLF发生的最高预测价值。
  • 新评分风险分层显示高风险(≥6.3)和低风险(<6.3)两层ACLF发生风险。

关键数值与推荐

  • COSSH-onset-ACLF评分公式:0.101 × ln[丙氨酸氨基转移酶] + 0.819 × ln[总胆红素] + 2.820 × ln[国际标准化比值] + 0.016 × ln[铁蛋白]。
  • 风险分层界值:≥6.3为高风险,<6.3为低风险。

临床怎么用

  • 新评分可能用于指导乙型肝炎病毒相关慢性肝病急性恶化患者的临床管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Acute-on-chronic liver failure (ACLF) is a life-threatening syndrome with rapid progression. This study aimed to develop and validate a prognostic score to predict the onset of ACLF in hepatitis B virus (HBV) etiology. METHODS: The prospective clinical data of 1373 patients with acute deterioration of HBV-related chronic liver disease were used to identify clinical characteristics and develop a prognostic score for the onset of ACLF. RESULTS: Of the patients assessed using the Chinese Group on the Study of Severe Hepatitis B (COSSH)-ACLF criteria, 903 patients with non-ACLF at admission (1 received transplantation at 5 days) were stratified: 71 with progression to ACLF and 831 without progression to ACLF at 7 days. Four predictors (total bilirubin, international normalized ratio, alanine aminotransferase, and ferritin) were associated significantly with ACLF onset at 7 days. The COSSH-onset-ACLF score was constituted as follows: (0.101 × ln [alanine aminotransferase] + 0.819 × ln [total bilirubin] + 2.820 × ln [international normalized ratio] + 0.016 × ln [ferritin]). The C-indexes of the new score for 7-/14-/28-day onset (0.928/0.925/0.913) were significantly higher than those of 5 other scores (Chronic Liver Failure Consortium ACLF development score/Model for End-stage Liver Disease score/Model for End-stage Liver Disease sodium score/COSSH-ACLF score/Chronic liver failure Consortium ACLF score; all P < .001). The improvement in predictive errors, time-dependent receiver operating characteristic, probability density function evaluation, and calibration curves of the new score showed the highest predictive value for ACLF onset at 7/14/28 days. Risk stratification of the new score showed 2 strata with high and low risk (≥6.3/<6.3) of ACLF onset. The external validation group further confirmed the earlier results. CONCLUSIONS: A new prognostic score based on 4 predictors can accurately predict the 7-/14-/28-day onset of ACLF in patients with acute deterioration of HBV-related chronic liver disease and might be used to guide clinical management.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Luo J, Liang X, Xin J, et al. Predicting the Onset of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. Clin Gastroenterol Hepatol. 2022. PMID: 35337983. doi:10.1016/j.cgh.2022.03.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。